GlassScriptPhysician profile
Brian C Phung
NPI 1588223382
$2,598.61
in general payments reported to CMS, 2019-2025
22 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $827 · 2024: $948 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,294.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.66 | 2022-2025 | |
| Amgen INC. | $265.86 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $249.48 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $217.68 | 2022-2025 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $206.12 | 2024 | Austedo Xr |
| Lilly USA, LLC | $186.36 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $181.00 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $156.31 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $121.71 | 2023 | Vemlidy |
| Sunovion Pharmaceuticals INC. | $93.36 | 2022 | |
| Merck Sharp & Dohme LLC | $82.73 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Nestle Healthcare Nutrition INC. | $74.75 | 2023 | |
| Aimmune Therapeutics, INC. | $61.81 | 2025 | Zenpep |
| Seqirus USA INC | $55.86 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Pfizer INC. | $38.41 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $33.19 | 2024 | Arikayce |
| Medtronic, INC. | $26.61 | 2025 | Venaseal |
| Edwards Lifesciences Corporation | $25.68 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ironwood Pharmaceuticals, INC | $23.62 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.24 | 2022 | |
| Phathom Pharmaceuticals, INC. | $21.29 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.